세계의 맞춤형 암 백신 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 기술별, 유통 채널별, 지역별, 부문 예측(2025-2030년)

Personalized Cancer Vaccine Market Growth & Trends:

The global personalized cancer vaccine market size is expected to reach USD 1.45 billion by 2030, registering a CAGR of 44.86% from 2025 to 2030, according to a new report by Grand View Research, Inc. The convergence of immunotherapy, genomics, and mRNA technologies drives the market growth. Unlike traditional vaccines, these personalized therapies are tailored to each patient's unique tumor profile, targeting neoantigens that arise from specific genetic mutations. This precision has opened new therapeutic horizons in oncology, especially for hard-to-treat cancers. The market growth is propelled by increasing investments in biotechnology, growing incidence of cancer worldwide, and advancements in next-generation sequencing. The rapid progression from clinical trials to regulatory designations, such as the European Medicines Agency's PRIME designation for Moderna and Merck's mRNA-4157/V940 in April 2023, is emblematic of this momentum. These vaccines are no longer speculative treatments; they are becoming integral to the future oncology landscape.

One of the most pivotal drivers of market growth is innovation in mRNA-based vaccine platforms. The success of COVID-19 mRNA vaccines accelerated public and private sector confidence in the modality, leading to increased funding and faster regulatory pathways. Moderna's investigational vaccine, mRNA-4157/V940, developed in partnership with Merck, exemplifies this progress. Granted PRIME designation by the EMA in April 2023, the vaccine showed promising results in Phase 2b trials (KEYNOTE-942), especially when paired with Merck's immunotherapy drug KEYTRUDA. Similarly, BioNTech, a pioneer in mRNA technology, showcased its oncology pipeline at the AACR Annual Meeting in April 2024, highlighting its mRNA-based cancer vaccines and antibody-drug conjugates. These innovations are allowing researchers to rapidly generate vaccine candidates based on tumor sequencing, personalize therapies in near real-time, and fine-tune immune responses to enhance efficacy, paving the way for a new era in cancer treatment.

Increased global awareness regarding HPV transmission, associated health risks, and the benefits of vaccination is a major factor driving market growth. Public health campaigns, social media outreach, and school-based education initiatives have played a pivotal role in changing perceptions and encouraging vaccine acceptance. In countries with robust healthcare communication strategies, such as Australia and the UK, HPV vaccine uptake is notably high, reflecting the impact of consistent, evidence-based awareness efforts. Gender-neutral vaccination messaging has also improved acceptance among male populations, particularly in response to the growing incidence of oropharyngeal and anal cancers in men. As stigma around sexual health diminishes and more people recognize the long-term cancer prevention benefits of vaccination, broader demographic groups are being reached. These awareness initiatives are not only increasing demand but are also leading to earlier vaccination, higher compliance rates, and more consistent market growth.

Regulatory incentives are playing a crucial role in accelerating the personalized cancer vaccine industry. Programs like the EMA's PRIME scheme or the FDA's Breakthrough Therapy designation are designed to expedite the development of promising therapies for serious conditions. Moderna and Merck's mRNA-4157/V940 vaccine receiving PRIME status is a testament to the regulators' commitment to fostering innovation in oncology. This designation was based on positive interim data suggesting that patients with high-risk stage III/IV melanoma had improved outcomes post-surgery when treated with the vaccine alongside KEYTRUDA. Similarly, BioNTech's participation in major scientific forums like AACR 2024, where it revealed significant clinical updates, underscores growing regulatory and scientific validation. These developments help boost investor confidence, shorten time-to-market for novel therapies, and offer hope for cancer patients who have limited treatment options, especially in the adjuvant setting.

Personalized Cancer Vaccine Market Report Highlights:

• Based on type, the dendritic cell segment accounted for the largest market share of 100% in 2024, driven by increasing demand for targeted and individualized immunotherapies.
• The cell-based technology segment led the market with a 100% revenue share in 2024, underpinned by its ability to harness the body's own immune system for targeted and adaptive anti-tumor responses. This segment includes therapies that utilize patient-derived cells, particularly dendritic cells, tumor-infiltrating lymphocytes (TILs), or engineered T-cells, to present tumor-specific antigens and stimulate a personalized immune attack against cancer cells.
• The hospitals segment dominated the market with a revenue share of 58.87% in 2024 and is expected to grow at the fastest CAGR over the forecast period, driven by several key factors. Hospitals serve as primary centers for cancer diagnosis, treatment, and follow-up care
• North America dominated the global market, with a share of 34.07% in 2024, driven by advancements in immunotherapy and a strong healthcare infrastructure. This growth is fueled by the increasing prevalence of cancer, with the U.S. alone reporting an estimated 1.9 million new cancer cases in 2022.
• The global personalized vaccine industry is led by several major companies, including Dendreon Pharmaceuticals, LLC, Gritstone Bio, CureVac, NeoCura & Innovent, Stemirna Therapeutics, Dendreon Pharmaceuticals, LLC, Elicio Therapeutics, Evaxion Biotech, Imugene, and Nouscom, all of which are strengthening their worldwide presence through strategies like launching new products, forging strategic partnerships, and expanding into new geographic regions.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Technology
  • 1.2.3. Distribution Channel
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Technology outlook
  • 2.2.3. Distribution channel outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Personalized Cancer Vaccine Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Trends and Outlook
• 3.4. Market Dynamics
  • 3.4.1. Advances in genomic and immunotherapy technologies
  • 3.4.2. Rising cancer prevalence and demand for targeted treatments
  • 3.4.3. Collaborations and increased investment in cancer immunotherapy
• 3.5. Market Restraint Analysis
  • 3.5.1. High development and manufacturing costs
  • 3.5.2. Regulatory and logistical challenges
  • 3.5.3. Porter's Five Forces Analysis
  • 3.5.4. PESTEL Analysis

Chapter 4. Personalized Cancer Vaccine Market: Type Estimates & Trend Analysis

• 4.1. Personalized Cancer Vaccine Market: Type Movement Analysis
• 4.2. Personalized Cancer Vaccine Market Estimates and Forecast, by Type
• 4.3. Dendritic Cell
  • 4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.4. RNA-Based (mRNA)
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Neoantigen-Based
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Tumor-Associated Antigen (TAA) Vaccines
  • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Personalized Cancer Vaccine Market: Technology Movement Analysis
• 4.8. Personalized Cancer Vaccine Market Estimates and Forecast, by Technology
• 4.9. Cell-based
  • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.10. mRNA PCV
  • 4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.11. Others
  • 4.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Personalized Cancer Vaccine Market: Distribution Channel Estimates & Trend Analysis

• 5.1. Personalized Cancer Vaccine Market: Distribution Movement Analysis
• 5.2. Personalized Cancer Vaccine Market Estimates and Forecast, by Distribution Channel
• 5.3. Hospitals
  • 5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.4. Clinics
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Research & Academic Institutes
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Personalized Cancer Vaccine Market: Regional Estimates & Trend Analysis

• 6.1. Personalized Cancer Vaccine Market Share By Region, 2024 & 2030
• 6.2. Regional Market Share Analysis, 2024 & 2030
• 6.3. Regional Market Dashboard
• 6.4. Global Regional Market Snapshot
• 6.5. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.6. North America
  • 6.6.1. North America Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.6.2. U.S.
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Competitive Scenario
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. U.S. Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.6.3. Canada
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Competitive Scenario
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Canada Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.6.4. Mexico
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Competitive Scenario
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. Mexico Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• 6.7. Europe
  • 6.7.1. Europe Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.7.2. UK
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Competitive Scenario
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. UK Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.7.3. Germany
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Competitive Scenario
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. Germany Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.7.4. France
    • 6.7.4.1. Key Country Dynamics
    • 6.7.4.2. Competitive Scenario
    • 6.7.4.3. Regulatory Framework
    • 6.7.4.4. France Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.7.5. Italy
    • 6.7.5.1. Key Country Dynamics
    • 6.7.5.2. Competitive Scenario
    • 6.7.5.3. Regulatory Framework
    • 6.7.5.4. Italy Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.7.6. Spain
    • 6.7.6.1. Key Country Dynamics
    • 6.7.6.2. Competitive Scenario
    • 6.7.6.3. Regulatory Framework
    • 6.7.6.4. Spain Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.7.7. Denmark
    • 6.7.7.1. Key Country Dynamics
    • 6.7.7.2. Competitive Scenario
    • 6.7.7.3. Regulatory Framework
    • 6.7.7.4. Denmark Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.7.8. Sweden
    • 6.7.8.1. Key Country Dynamics
    • 6.7.8.2. Competitive Scenario
    • 6.7.8.3. Regulatory Framework
    • 6.7.8.4. Sweden Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.7.9. Norway
    • 6.7.9.1. Key Country Dynamics
    • 6.7.9.2. Competitive Scenario
    • 6.7.9.3. Regulatory Framework
    • 6.7.9.4. Norway Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• 6.8. Asia Pacific
  • 6.8.1. Asia Pacific Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.8.2. Japan
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Competitive Scenario
    • 6.8.2.3. Regulatory Framework
    • 6.8.2.4. Japan Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.8.3. China
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Competitive Scenario
    • 6.8.3.3. Regulatory Framework
    • 6.8.3.4. China Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.8.4. India
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Competitive Scenario
    • 6.8.4.3. Regulatory Framework
    • 6.8.4.4. India Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.8.5. Australia
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Competitive Scenario
    • 6.8.5.3. Regulatory Framework
    • 6.8.5.4. Australia Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.8.6. Thailand
    • 6.8.6.1. Key Country Dynamics
    • 6.8.6.2. Competitive Scenario
    • 6.8.6.3. Regulatory Framework
    • 6.8.6.4. Thailand Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.8.7. South Korea
    • 6.8.7.1. Key Country Dynamics
    • 6.8.7.2. Competitive Scenario
    • 6.8.7.3. Regulatory Framework
    • 6.8.7.4. South Korea Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• 6.9. Latin America
  • 6.9.1. Latin America Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.9.2. Brazil
    • 6.9.2.1. Key Country Dynamics
    • 6.9.2.2. Competitive Scenario
    • 6.9.2.3. Regulatory Framework
    • 6.9.2.4. Brazil Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.9.3. Argentina
    • 6.9.3.1. Key Country Dynamics
    • 6.9.3.2. Competitive Scenario
    • 6.9.3.3. Regulatory Framework
    • 6.9.3.4. Argentina Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• 6.10. MEA
  • 6.10.1. MEA Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.10.2. South Africa
    • 6.10.2.1. Key Country Dynamics
    • 6.10.2.2. Competitive Scenario
    • 6.10.2.3. Regulatory Framework
    • 6.10.2.4. South Africa Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.10.3. Saudi Arabia
    • 6.10.3.1. Key Country Dynamics
    • 6.10.3.2. Competitive Scenario
    • 6.10.3.3. Regulatory Framework
    • 6.10.3.4. Saudi Arabia Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.10.4. UAE
    • 6.10.4.1. Key Country Dynamics
    • 6.10.4.2. Competitive Scenario
    • 6.10.4.3. Regulatory Framework
    • 6.10.4.4. UAE Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.10.5. Kuwait
    • 6.10.5.1. Key Country Dynamics
    • 6.10.5.2. Competitive Scenario
    • 6.10.5.3. Regulatory Framework
    • 6.10.5.4. Kuwait Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company Categorization
• 7.3. Strategy Mapping
• 7.4. Company Market Share Analysis, 2024
• 7.5. Company Profiles
  • 7.5.1. Dendreon Pharmaceuticals, LLC
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Gritstone Bio
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. CureVac
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. NeoCura & Innovent
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. Stemirna Therapeutics
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. Elicio Therapeutics
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. Evaxion Biotech
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. Imugene
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. Nouscom
    • 7.5.9.1. Overview
    • 7.5.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives